turnaround times across care settings. For example, in breast cancer, patients treated in academic institutions assessed tumor types in the last five years (Exhibit 2), may receive biomarker testing results via PCR, IHC, driven by growing clinical evidence, regulatory approvals, and integration into national guidelines such in community hospitals. However, among patients with NSCLC, those tested in community settings may receive PCR and NGS results six days and two days earlier, on stakeholder consensus on their benefit. Discussions respectively, compared to those tested in academic with oncologists, pathologists, and laboratory directors 1. Generation of robust evidence demonstrating biomarker utility, typically followed by approval and downstream processes, including payer coverage, laboratory standardization, real-world evidence generation, and post-marketing learning around the 2. Formal inclusion of testing recommendations in
研搜
0731-84720580
商务合作：really158d
下载Excel
下载图片
原图定位
打包全文图表
收藏
2026-07-21
原图定位
微信扫码登录
手机快捷登录
账号登录
